Stockscreener 앱 받기
2.5051
7.51%
0.1751
전일 마감가:
$2.33
열려 있는:
$2.62
하루 거래량:
588.74K
Relative Volume:
1.07
시가총액:
$20.22M
수익:
$1.73M
순이익/손실:
$-23.50M
주가수익비율:
-0.5735
EPS:
-4.3682
순현금흐름:
$-19.37M
1주 성능:
-5.11%
1개월 성능:
-25.93%
6개월 성능:
-69.60%
1년 성능:
-75.92%
1일 변동 폭
$2.4501
$2.78
1주일 범위
$2.17
$2.78
52주 변동 폭
$2.17
$18.80
VolitionRX Ltd Stock (VNRX) Company Profile
명칭
VolitionRX Ltd
전화
646 650 1351
주소
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
2.50 | 18.84M | 1.73M | -23.50M | -19.37M | -4.3682 |
TMO
Thermo Fisher Scientific Inc
|
475.48 | 173.46B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
175.60 | 123.60B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
575.73 | 44.71B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
119.59 | 33.21B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
353.12 | 33.65B | 3.77B | 449.25M | 516.49M | 8.7322 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | H.C. Wainwright | Buy |
| 2023-02-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-02-17 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-05-16 | 개시 | Maxim Group | Buy |
| 2018-05-14 | 재확인 | The Benchmark Company | Buy |
| 2016-09-07 | 재확인 | Rodman & Renshaw | Buy |
| 2016-02-01 | 개시 | Rodman & Renshaw | Buy |
모두보기
VolitionRX Ltd 주식(VNRX)의 최신 뉴스
A blood test for cat lymphoma showed 86% detection at 97% specificity - Stock Titan
VolitionRx Limited 2025 Annual Report: Executive Compensation, Director Ownership, and Corporate Governance Insights - Minichart
VNRX Stock Price, Quote & Chart | VOLITIONRX LTD (NYSEARCA:VNRX) - ChartMill
VolitionRX Limited (VNRX) Investment Case | Q4 2025: Earnings UnderperformEV/EBITDA - Newser
CEO pay, board changes and reverse split at VolitionRx (NYSE: VNRX) - Stock Titan
VolitionRx (VNRX) Achieves Breakthrough in Sepsis Detection with New Test - GuruFocus
Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing - Barchart.com
VolitionRx Limited Announces Amendment to Certificate of Incorporation in April 2026 8-K Filing - Minichart
VolitionRx (NYSE: VNRX) implements 1-for-20 reverse stock split - Stock Titan
DISCLOSED: 5 Stocks Congress Just Bought (PC6HZG2Kcg) - Fathom Journal
VolitionRX | 8-K: Current report - Moomoo
VNRX Should I Buy - Intellectia AI
VolitionRx receives NYSE American compliance plan approval By Investing.com - Investing.com Australia
VolitionRx receives NYSE American compliance plan approval - Investing.com
VolitionRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VolitionRx (NYSE: VNRX) wins NYSE American time to fix listing - Stock Titan
VolitionRx shares stay on NYSE as exchange accepts compliance plan - Stock Titan
D Boral Capital downgrades VolitionRx (VNRX) - MSN
VolitionRx launches online shop for recombinant nucleosomes By Investing.com - Investing.com Australia
VNRX Downgraded by D. Boral Capital -- Rating Changed to Hold - GuruFocus
VolitionRx Ltd stock (US92852X1037): Does its blood-testing tech unlock real diagnostic upside? - AD HOC NEWS
D. Boral Capital downgrades VolitionRX stock rating on reverse split By Investing.com - Investing.com South Africa
D. Boral Capital Downgrades VolitionRX(VNRX.US) to Hold Rating - Moomoo
After building for 10 years, Volition puts nucleosomes up for sale online - Stock Titan
VolitionRx Limited Files Form 8-K With SEC Detailing Company Information and Compliance Data - Minichart
VolitionRx Ltd stock (US92852X1037): Is its blood-testing breakthrough strong enough to unlock inves - AD HOC NEWS
VolitionRx Sets One-for-Twenty Reverse Stock Split - The Globe and Mail
VolitionRx (VNRX) to execute 1-for-20 reverse stock split on April 28, 2026 - Stock Titan
Volition approves 1-for-20 reverse stock split effective April 28, 2026 - TradingView
VolitionRx Ltd stock (US92852X1037): Why does its blood-testing innovation matter more now for U.S. - AD HOC NEWS
H.C. Wainwright cuts VolitionRX stock price target to $1 on share count - Investing.com Australia
VolitionRx Earnings Call: Breakthroughs Amid Funding Strain - TipRanks
VolitionRx Limited (VNRX) stock price, news, quote and history - Yahoo Finance UK
VNRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
VolitionRX (VNRX) FY2025 Earnings: Q4 EPS and Revenue Not Disclo - GuruFocus
VolitionRX Is Maintained at Buy by HC Wainwright & Co. - Moomoo
VolitionRx Limited (AMEX:VNRX) Q4 2025 Earnings Call Transcript - Insider Monkey
VolitionRX Q4 Earnings Call Highlights - Defense World
VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong R - GuruFocus
VolitionRx: Robust Revenue Growth and Promising Capture-Seq Data Support Buy Rating Despite Dilution-Driven Target Cut - TipRanks
VolitionRX (VNRX) Sees Target Price Cut Despite Maintained Buy R - GuruFocus
VolitionRx Limited (VNRX) 8-K SEC Filing March 31, 2026: Company Details, Address, and Stock Information - Minichart
VolitionRx (NYSE: VNRX) wins approval for major share issue and reverse split - Stock Titan
Earnings call transcript: VolitionRx Q4 2025 reveals mixed financial results By Investing.com - Investing.com South Africa
Earnings call transcript: VolitionRx Q4 2025 reveals mixed financial results - Investing.com
Q4 2025 VolitionRX Ltd Earnings Call Transcript - GuruFocus
VolitionRx : Corporate Presentation April 2026 - marketscreener.com
VolitionRX Ltd (VNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.07%
0.32%
자본화:
|
볼륨(24시간):